-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
BiondVax Pharmaceuticals (NASDAQ:BVXV) Versus Bio-Techne (NASDAQ:TECH) Head-To-Head Contrast
BiondVax Pharmaceuticals (NASDAQ:BVXV) Versus Bio-Techne (NASDAQ:TECH) Head-To-Head Contrast
Bio-Techne (NASDAQ:TECH – Get Rating) and BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
Institutional & Insider Ownership
23.9% of Bio-Techne shares are held by institutional investors. 4.5% of Bio-Techne shares are held by insiders. Comparatively, 6.0% of BiondVax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Get Bio-Techne alerts:Valuation and Earnings
This table compares Bio-Techne and BiondVax Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bio-Techne | $1.12 billion | 11.05 | $272.05 million | $1.78 | 44.20 |
BiondVax Pharmaceuticals | N/A | N/A | -$12.85 million | ($4.04) | -0.64 |
Volatility and Risk
Bio-Techne has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, BiondVax Pharmaceuticals has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Bio-Techne and BiondVax Pharmaceuticals, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bio-Techne | 0 | 2 | 5 | 0 | 2.71 |
BiondVax Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Bio-Techne currently has a consensus target price of $107.86, indicating a potential upside of 37.09%. Given Bio-Techne's higher probable upside, research analysts clearly believe Bio-Techne is more favorable than BiondVax Pharmaceuticals.
Profitability
This table compares Bio-Techne and BiondVax Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Bio-Techne | 26.13% | 16.37% | 12.16% |
BiondVax Pharmaceuticals | N/A | -230.46% | -35.35% |
Summary
Bio-Techne beats BiondVax Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
About Bio-Techne
(Get Rating)
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T
About BiondVax Pharmaceuticals
(Get Rating)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
Bio-Techne (NASDAQ:TECH – Get Rating) and BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
生物科技(納斯達克:TECH-GET評級)和生物威士製藥(納斯達克:BVXV-GET評級)都是醫藥公司,但哪隻股票更優?我們將根據這兩家公司的風險、估值、機構所有權、收益、盈利能力、股息和分析師的建議來比較它們的實力。
Institutional & Insider Ownership
機構與內部人持股
23.9% of Bio-Techne shares are held by institutional investors. 4.5% of Bio-Techne shares are held by insiders. Comparatively, 6.0% of BiondVax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Bio-Techne公司23.9%的股份由機構投資者持有。Bio-Techne 4.5%的股份由內部人士持有。相比之下,BiondVax PharmPharmticals 6.0%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一家公司的長期表現將好於大盤。
Valuation and Earnings
估值和收益
This table compares Bio-Techne and BiondVax Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
該表格比較了Bio-Techne和BiondVax製藥公司的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bio-Techne | $1.12 billion | 11.05 | $272.05 million | $1.78 | 44.20 |
BiondVax Pharmaceuticals | N/A | N/A | -$12.85 million | ($4.04) | -0.64 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
生物技術 | 11.2億美元 | 11.05 | 2.7205億美元 | $1.78 | 44.20 |
BiondVax製藥 | 不適用 | 不適用 | -1,285萬元 | ($4.04) | -0.64 |
Volatility and Risk
波動性和風險
Bio-Techne has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, BiondVax Pharmaceuticals has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.
BioTechne的貝塔係數為1.25,這表明其股價的波動性比標準普爾500指數高出25%。相比之下,BiondVax PharmPharmticals的貝塔係數為2.65,這表明其股價的波動性比標準普爾500指數高165%。
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and price targets for Bio-Techne and BiondVax Pharmaceuticals, as reported by MarketBeat.com.
據MarketBeat.com報道,這是Bio-Techne和BiondVax製藥公司最近的評級和目標價細分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bio-Techne | 0 | 2 | 5 | 0 | 2.71 |
BiondVax Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
生物技術 | 0 | 2 | 5 | 0 | 2.71 |
BiondVax製藥 | 0 | 0 | 0 | 0 | 不適用 |
Bio-Techne currently has a consensus target price of $107.86, indicating a potential upside of 37.09%. Given Bio-Techne's higher probable upside, research analysts clearly believe Bio-Techne is more favorable than BiondVax Pharmaceuticals.
BioTechne目前的共識目標價為107.86美元,表明潛在上漲37.09%。鑑於Bio-Techne更有可能上行,研究分析師顯然認為Bio-Techne比BiondVax PharmPharmticals更有利。
Profitability
盈利能力
This table compares Bio-Techne and BiondVax Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了Bio-Techne和BiondVax製藥公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Bio-Techne | 26.13% | 16.37% | 12.16% |
BiondVax Pharmaceuticals | N/A | -230.46% | -35.35% |
淨利潤率 | 股本回報率 | 資產回報率 | |
生物技術 | 26.13% | 16.37% | 12.16% |
BiondVax製藥 | 不適用 | -230.46% | -35.35% |
Summary
摘要
Bio-Techne beats BiondVax Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
在兩隻股票的12項指標中,BioTechne有10項超過了BiondVax PharmPharmticals。
About Bio-Techne
關於生物技術公司
(Get Rating)
(獲取評級)
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T
生物技術公司致力於為研究和臨牀診斷市場開發、製造和銷售生物技術試劑和儀器。它通過以下部門運作:蛋白質科學和診斷以及基因組學。蛋白質科學部門開發和製造純化的蛋白質和試劑溶液,最主要的是細胞因子和生長因子、抗體、免疫分析、生物活性小分子化合物、組織培養試劑和T細胞激活技術。這一領域還包括蛋白質分析解決方案,為研究人員提供高效和簡化的自動化蛋白質印跡和多路酶聯免疫吸附試驗工作流程選項。診斷和基因組學部門開發和製造診斷產品,包括用於OEM和臨牀客户的FDA規定的對照、校準器、血氣和臨牀化學對照和其他試劑,以及臨牀分子診斷腫瘤學分析組合,包括用於前列腺癌診斷的ExoDx前列腺癌(IntelliScore)測試(EPI)。這一部門還製造和銷售先進的組織原位雜交分析(ISH),用於研究和臨牀使用。T
About BiondVax Pharmaceuticals
關於BiondVax製藥公司
(Get Rating)
(獲取評級)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
BiondVax製藥有限公司是一家臨牀階段的生物製藥公司,致力於傳染病免疫調節療法的開發和商業化。它的重點是候選流感疫苗,該疫苗旨在提供針對季節性和大流行性流感的多毒株和多季節保護。該公司由Ronald Babecoff和Rami Epstein於2003年7月21日創立,總部設在以色列耶路撒冷。
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《生物技術日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Bio-Techne及相關公司評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧